But wasn't Itolizumab already approved in India (i
Post# of 145528
In hindsight, I wonder how things would be different if CYDY did a small (e.g. 20-25 patients ) phase 1 severe/critical trail back in late March/early April. Could quick positive results for such a trial have powered greater enrollment in larger subsequent trials that would all be completed by now?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)